UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis

Authors
Michael Emmett, MD
Biff F Palmer, MD
Section Editor
Richard H Sterns, MD
Deputy Editor
John P Forman, MD, MSc

INTRODUCTION

The approach to therapy in distal (type 1) and proximal (type 2) renal tubular acidosis (RTA) is determined by the primary defect in each disorder: decreased distal acidification and impaired proximal bicarbonate reabsorption, respectively [1]. Correction of the acidosis may have a variety of benefits, including restoration of normal growth in children [2], diminished renal potassium wasting and hypokalemia in distal RTA, stabilization or reversal of nephrocalcinosis, reduced frequency of calcium kidney stones, and possibly less osteoporosis in distal RTA and less rickets or osteomalacia in proximal RTA [3]. Adequately treated patients are generally asymptomatic and able to lead a normal life, unless irreversible renal or bone disease has occurred prior to therapy.

The treatment of distal and proximal RTA will be reviewed here. The pathogenesis, etiology, and diagnosis of these disorders are discussed separately. (See "Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance" and "Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis".)

DISTAL (TYPE 1) RENAL TUBULAR ACIDOSIS

Adults ingesting a typical American or Western European diet generate approximately 1 to 1.5 meq/kg of acid per day that is excreted by the kidneys in the form of titratable acids or ammonium. Patients with distal renal tubular acidosis (distal RTA) have a reduction in ammonium excretion and are unable to maximally lower the urine pH, resulting in the excretion of only part of the daily acid load. Thus, the daily alkali requirement is equal to the amount of hydrogen retained each day plus any urinary bicarbonate losses obligated by the high urine pH. The small amount of urine bicarbonate loss in patients with distal RTA is obligated by the relationship expressed by the Henderson-Hasselbalch equation. It does not represent a defect in bicarbonate reabsorption as in proximal RTA. If, for example, the urine pH is 6.4, the urine bicarbonate concentration will be approximately one-tenth (one log unit) that of the plasma or about 2 meq/L (assuming similar carbon dioxide tensions).

Correction of the metabolic acidosis has a number of beneficial effects. It restores normal growth rates in children, minimizes kidney stone formation and nephrocalcinosis, and diminishes calcium losses associated with bone buffering of some of the retained acid, thereby decreasing the risk of osteopenia. (See "Nephrolithiasis in renal tubular acidosis", section on 'Distal (type 1) RTA'.)

In addition, correction of the metabolic acidosis with alkali therapy (eg, sodium bicarbonate or sodium citrate) reduces inappropriate urinary potassium losses, which often corrects the associated hypokalemia [1,3-7]. Potassium depletion in these patients results from a reduction in proximal sodium reabsorption induced by metabolic acidosis [8,9]. The subsequent increase in sodium excretion leads to volume contraction and activation of the renin-angiotensin-aldosterone system. The combination of increased distal sodium delivery and aldosterone increases renal potassium excretion. (See "Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance", section on 'Decreased net activity of the proton pump'.)

  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jul 19 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.612.
  2. McSherry E. Renal tubular acidosis in childhood. Kidney Int 1981; 20:799.
  3. Morris RC Jr, Sebastian A. Alkali therapy in renal tubular acidosis: who needs it? J Am Soc Nephrol 2002; 13:2186.
  4. Coe FL, Parks JH. Stone disease in hereditary distal renal tubular acidosis. Ann Intern Med 1980; 93:60.
  5. Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134:20.
  6. Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.
  7. Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V, et al. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int 2002; 62:2160.
  8. Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 2011; 22:1981.
  9. Wang T, Egbert AL Jr, Aronson PS, Giebisch G. Effect of metabolic acidosis on NaCl transport in the proximal tubule. Am J Physiol 1998; 274:F1015.
  10. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 2002; 13:2160.
  11. Sebastian A, McSherry E, Morris RC Jr. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest 1971; 50:231.
  12. Donckerwolcke RA, van Stekelenburg GJ, Tiddens HA. Therapy of bicarbonate-losing renal tubular acidosis. Arch Dis Child 1970; 45:774.
  13. Nash MA, Torrado AD, Greifer I, et al. Renal tubular acidosis in infants and children. Clinical course, response to treatment, and prognosis. J Pediatr 1972; 80:738.